Patent · US Active

Cultured phagocyte supernatent compositions

US11793865B2 · kind B2 · utility

1Cited by

0References

11Claims

0Family size

Assignees

Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
ETABLISSEMENT FRANCAIS DU SANG (EFS) · FR
UNIVERSITE DE FRANCHE-COMTE · FR
Centre Hospitalier Regional Et Universitaire De Brest · FR

Inventors

Sylvain Perruche · Placey, FR
Philippe SAAS · Besançon, FR
Francis Bonnefoy · Terminal 1 - Part B, FR

Key dates

Filing date	Apr 14, 2020
Grant date	Oct 24, 2023
Priority date	—
Expiry date	Sep 2, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/435
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.